

Introducing COPDPredict™




Unique digital monitoring specifically designed to provide personalised prediction of exacerbations to COPD patients with frequent/severe episodes.

- CE marked, OSWAP compliant and registered with NHS Digital.
- Automatically creates patient-centric bioclinical profiles.
- AI-enabled prediction algorithms identify changes in health, instantly alerting on impending exacerbations.
- Allows timely and efficient intervention, preventing unnecessary hospitalisations.
- Assists COVID-19 pathways for COPD patients enabling close monitoring at home and early identification/triage of those needing treatment escalation.

How COPDPredict™ works

<https://vimeo.com/448588678/f2db0461e5>



COPDPredict™ is timely & can transform COPD care pathways at 2 pain points:

- 1) In the community, for patients experiencing frequent exacerbations/severe episodes (*GOLD 1-4, groups C&D*) to prevent unnecessary hospitalisations.
- 2) In hospitals, as part of the discharge bundle to save bed-days and prevent readmissions.

Evidence it works

NIHR funded study: **90 frequently exacerbator patients** (age range 48 to 91yrs; FEV₁ 15 to 86% predicted) with at least 1 hospitalisation in prior 12 months demonstrated clinically significant reduction in hospitalisations (4 versus 45 expected), saving NHS Trust £3,200/patient and releasing 448 bed days. Positive patient experience with 98% compliance with self-assessment.

COPDPredict™ makes home-based care for people with COPD more efficient, prevents unnecessary A&E visits & hospitalisations and can deliver cost savings instantly.

NEPESMO Limited

Registered in England and Wales: 11071606. VAT Reg. Number 290 4036 19

Business Address: 76 King Street, Manchester M2 4NH, United Kingdom

T: +44(0) 161 817 8080 W: www.nepsemo.com